Richard A. Larson to Australia
This is a "connection" page, showing publications Richard A. Larson has written about Australia.
Connection Strength
0.024
-
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
Score: 0.024